"European Union (EU) regulatory clearance is a strategic milestone
for CeMines. While this event clearly represents an essential
'validation' of our molecular diagnostic technology, it also serves as
a vital catalyst, enabling CeMines to proceed with final preparations
necessary to commercialize this 'first to market' product from our
CellCorrect family of molecular diagnostic kits. Simply stated,
CeMines will soon offer physicians across Europe a broader range of
less invasive Dx tools to assist them in detection and diagnosis of
cancer."
